Infliximab

Hospira launch biosimilar mAb in the EU

Hospira launches first mAb biosimilar in major EU markets

By Zachary Brennan

Hospira, recently acquired by Pfizer, announced Monday the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets, following the patent expiry of J&J’s Remicade.